Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pavel Chrbolka"'
Autor:
Zoltán, Paluch, Lilla, Biriczová, Gergely, Pallag, Pavel, Chrbolka, Natalia, Vargová, Emanuel, Marques, Štefan, Alušík, Jana, Hercogová, Kamila, Hůrková, Jana, Hajšlová
Publikováno v:
In Journal of Herbal Medicine December 2023 42
Autor:
Zoltan, Paluch, Milan, Trojánek, Zuzana, Velíšková, Jana, Mlíchová, Pavel, Chrbolka, Jana, Gregorová, Emanuel, Marques, Dagmar, Kalatova, Dušan, Pícha
Publikováno v:
Neuro endocrinology letters. 42(6)
Acyclovir is an antiviral drug frequently used in clinical practice. It is indicated for the treatment of infections caused by herpes simplex virus and varicella zoster virus. The drug has a good safety profile; however, severe side effects may rarel
Autor:
Hinrich Staecker, Timothy Kramer, Thomas Meyer, Joong Ho Ahn, Michael Morelock, Pavel Chrbolka
Publikováno v:
Otolaryngology--Head and Neck Surgery
Objective To evaluate the safety and tolerability of repeated intratympanic administration of the gel-formulated NMDA receptor antagonist AM-101 in acute patients with inner ear tinnitus. Study Design Prospective, double-blind, randomized, placebo-co
Publikováno v:
Neuro endocrinology letters. 41(2)
The aim of our study was to establish whether or not tinnitus patients have higher platelet activity, as measured by plasma 11-dehydro-thromboxane B2 levels, compared with individuals without tinnitus.The study group included patients without documen
Publikováno v:
Steroids. 123
While not a disease entity in itself; symptoms of tinnitus (from Latin tinnio - clink) accompany a number of diseases. Tinnitus prevalence increases with age, deteriorates one's quality of life, and may even result in suicidal behavior. Tinnitus deve
Effective treatment of mild-to-moderate nasal polyposis with fluticasone delivered by a novel device
Autor:
Per G. Djupesland, Ingrid Vlckova, Pavel Pavlicek, Pavel Navratil, Radim Kana, Pavel Chrbolka
Publikováno v:
Rhinology journal. 47:419-426
Objective: To assess the efficacy and safety of fluticasone propionate administered using OptiNose's novel delivery device (Opt-FP) in subjects with bilateral mild-to-moderate nasal polyposis. Methods: A prospective, multicentre, randomized, double-b